Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 1;77(12):1572-1575.
doi: 10.1001/jamaneurol.2020.2743.

Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients With Myelin Oligodendrocyte Glycoprotein IgG-Associated Disorders

Amy Kunchok  1   2   3 , John J Chen  3   4 , Ruba S Saadeh  2   3 , Dean M Wingerchuk  5 , Brian G Weinshenker  1   2   3 , Eoin P Flanagan  1   2   3 , Sean J Pittock  1   2   3
Affiliations

Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients With Myelin Oligodendrocyte Glycoprotein IgG-Associated Disorders

Amy Kunchok et al. JAMA Neurol. .

Abstract

This study evaluates the proportion of patients with myelin oligodendrocyte glycoprotein IgG–associated disorders who fulfill the seronegative neuromyelitis optica spectrum disorder criteria.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Wingerchuk has received research funding from Alexion and TerumoBCT; personal compensation consulting for MedImmune, Novartis, Biogen, Celgene, Genentech, TG Therapeutics, Arcus Medica, Third Rock Ventures, and Reistone; and served on an adjudication committee for a neuromyelitis optica (NMO) clinical trial sponsored by MedImmune and Viela Bio. Dr Weinshenker receives royalties from RSR Ltd, Oxford University, Hospices Civil de Lyon, and MVZ Labor PD Dr Volkmann und Kollegen GbR for a patent of NMO-IgG as a diagnostic test for NMO and related disorders; served on adjudication committee for clinical trials in NMO conducted by MedImmune and Alexion; and consulted for Chugai and Mitsubishi Tanabe regarding clinical trials for NMO. Dr Flanagan is a site principal investigator in a randomized placebo-controlled clinical trial of inebilizumab (a CD19 inhibitor) in neuromyelitis optica spectrum disorders funded by MedImmune/Viela Bio. Dr Pittock reports grants, personal fees and nonfinancial support from Alexion Pharmaceuticals, Inc; grants from Grifols and Autoimmune Encephalitis Alliance; grants, personal fees, nonfinancial support, and other support from MedImmune Inc; Dr Pittock also has a patent (application 12-573942) “Methods for Treating Neuromyelitis Optica (NMO) by Administration of Eculizumab to an individual that is Aquaporin-4 (AQP4)-IgG Autoantibody positive.” Dr Pittock also has patents pending for the following IgGs as biomarkers of autoimmune neurological disorders: septin-5, Kelch-like protein 11, GFAP, PDE10A and MAP1B.

Figures

Figure.
Figure.. Magnetic Resonance Imaging Features of Patients With Myelin Oligodendrocyte Glycoprotein–IgG Associated Disorders Meeting and Not Meeting the Neuromyelitis Optica Spectrum Disorder (NMOSD) 2015 Seronegative Criteria
Meeting NMOSD 2015 Seronegative criteria: patient 1 (A) sagittal magnetic resonance imaging (MRI) T2 longitudinally extensive conus lesion (first attack), sagittal MRI T2 longitudinally extensive thoracic lesion from T7-T10 (B; second attack), and axial MRI with T2/fluid-attenuated inversion recovery periepenydmal brainstem lesion (C). Not meeting NMOSD 2015 seronegative criteria: patient 2 (D) axial MRI T2/fluid-attenuated inversion recovery large bilateral subcortical and periventricular lesions in the setting of acute disseminated encephalomyelitis in patient with history of recurrent optic neuritis. Patient 3 (E) axial MRI with brainstem medullary T2 lesion (not peripendymal) in a patient with recurrent optic neuritis.
See this image and copyright information in PMC

References

    1. Wingerchuk DM, Banwell B, Bennett JL, et al. ; International Panel for NMO Diagnosis . International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189. doi:10.1212/WNL.0000000000001729 - DOI - PMC - PubMed
    1. Kunchok A, Krecke KN, Flanagan EP, et al. . Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD)? Neurology. 2020;94(2):85-88. doi:10.1212/WNL.0000000000008786 - DOI - PubMed
    1. Dubey D, Pittock SJ, Krecke KN, et al. . Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol. 2019;76(3):301-309. doi:10.1001/jamaneurol.2018.4053 - DOI - PMC - PubMed
    1. Chen JJ, Flanagan EP, Jitprapaikulsan J, et al. . Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol. 2018;195:8-15. doi:10.1016/j.ajo.2018.07.020 - DOI - PMC - PubMed
    1. Jitprapaikulsan J, Chen JJ, Flanagan EP, et al. . Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis. Ophthalmology. 2018;125(10):1628-1637. doi:10.1016/j.ophtha.2018.03.041 - DOI - PubMed

Publication types